Pharmacological management of overactive bladderA systematic and critical review of published economic evaluations

被引：0
作者：
Denis Getsios
Wissam El-Hadi
Ingrid Caro
J. Jaime Caro
机构：
[1] Caro Research Institute,Division of General Internal Medicine
[2] Caro Research Institute,undefined
[3] Caro Research Institute,undefined
[4] McGill University Faculty of Medicine,undefined
来源：
PharmacoEconomics | 2005年 / 23卷
关键词：
Urinary Incontinence; Overactive Bladder; Oxybutynin; Urge Incontinence; Tolterodine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Overactive bladder is a common condition, with recent findings estimating the prevalence in adults at about 15%. Symptoms, including urinary urgency, high voiding frequency and urge incontinence, have been shown to decrease patients’ quality of life. Given its high prevalence, the economic burden of overactive bladder is also substantial, with a recent estimate placing the annual cost in the US at $US9.1 billion (year 2000 values). The objective of this review is to provide a critical appraisal of published economic evaluations of pharmacological and non-pharmacological treatments for overactive bladder.
引用
收藏
页码：995 / 1006
页数：11
相关论文
共 170 条
[21]  
Burger C.W.(2002)Pharmacotherapy of the overactive bladder and advances in drug delivery Clin Obstet Gynecol 45 205-17
[22]  
Lagace E.A.(2004)Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations Drugs 64 1643-56
[23]  
Hansen W.(2001)Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study Mayo Clin Proc 76 358-63
[24]  
Hickner J.M.(2003)Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial Mayo Clin Proc 78 687-95
[25]  
Thom D.(2002)Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the Antimuscarinic Clinical Effectiveness Trial (ACET) Curr Med Res Opin 19 177-84
[26]  
Schulman C.(2002)Methodologic shortcomings in a post-hoc analysis Curr Urol Rep 3 431-3
[27]  
Claes H.(1998)Economic costs of urinary incontinence in 1995 Urology 51 355-61
[28]  
Matthijs J.(2001)Annual direct costs of urinary incontinence Obstet Gynecol 98 398-406
[29]  
Hergoz A.R.(2001)Insurance claim costs for overactive bladder disorder Drug Benefit Trends 13 45-48
[30]  
Fultz N.H.(2002)Informal caregiving time and costs for urinary incontinence in older individuals in the United States J Am Geriatr Soc 50 733-7
12345678910